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Abstract An 85-year-old female with chronic kidney
disease and newly acquired seizures on oral phenytoin
received intravenous ertapenem 500 mg once daily for a
urinary tract infection and bacteraemia involving extended-
spectrum beta-lactamase (ESBL)-producing Escherichia
coli. After three ertapenem doses, she developed seizures
which self-aborted. Corrected phenytoin level was sub-
therapeutic initially, but became therapeutic following a
phenytoin dose increase. On Day 14 of ertapenem, the
patient suffered another episode of seizure. Ertapenem was
stopped. On Day 15, she developed status epilepticus
lasting 2 days, requiring intravenous lorazepam, sodium
valproate and phenytoin. The last episode of seizure
occurred 3 days after discontinuation of ertapenem, with a
dramatic recovery of her Glasgow Coma Scale and reso-
lution of delirium. At the time of writing, she has remained
seizure free for over 2 years. A retrospective audit of the
emergency department notes revealed that she had a course
of ertapenem in another institution prior, which also led to
two seizure episodes—once 8 days after starting ertape-
nem, another 3 days after stopping ertapenem. Despite
using a renal-adjusted ertapenem dose, each dip in her
creatinine clearance level was associated with seizures,
preceded by delirium each time. Naranjo assessment score
was 6, suggesting a probable relationship between the
seizures and ertapenem.
Key Points
There is a recognizable clinical pattern in the
manifestation of ertapenem-induced delirium and
seizures in the high-risk, very elderly patient.
Discontinuation of ertapenem therapy should be
considered if seizures develop and alternative
antibacterial therapy used instead if available.
High index of suspicion is required to detect and
report these unseen and highly complex adverse drug
reactions in clinical practice.
Although the incidence of ertapenem-induced
seizures is reportedly low in the general population,
more work and studies may be required to quantify
the risks for specific high-risk subgroups.
Introduction
Carbapenems are an important class of broad-spectrum
antibacterials for the treatment of complicated and serious
bacterial infections caused by Gram-positive and Gram-
negative organisms, especially extended-spectrum beta-
lactamase (ESBL)-producing Enterobacteriaceae. Ertape-
nem, a carbapenem, is advantageous in that it is long-acting
and allows for a convenient, once-daily dosing. This results
from the addition of a meta-substituted benzoic acid group,
granting it greater lipophilicity and a net negative charge at
physiological pH, hence greater plasma protein binding
ability compared with other carbapenems [1]. Its 1-b-
methyl substituent confers stability against hydrolysis by
& Samuel T. H. Chew
Samuel_Chew@cgh.com.sg
1 Changi General Hospital, Singapore, Singapore
Drug Saf - Case Rep (2015) 2:19
DOI 10.1007/s40800-015-0021-5
renal dehydropeptidase-1 (DHP-1), thus it does not require
concurrent administration with a DHP-1 inhibitor such as
cilastatin [1].
However, carbapenems have been widely implicated in
causing neurotoxicity, particularly seizures [2–4]. Most
reports of seizures were associated with the use of imipe-
nem-cilastatin at rates varying from 3 to 33 % while
occurrence of seizures with other carbapenems, including
ertapenem, were individually reported to be\1 % [3].
We present here a case of repeated ertapenem use in two
separate admissions under different primary medical
admitting teams in a very elderly patient ([80 years old)
with chronic kidney disease, low serum albumin and
incidental findings of silent small vessel cerebrovascular
disease resulting in delirium and seizures. Discontinuation
of ertapenem therapy was followed by complete and sus-
tained resolution of both delirium and seizures.
Case Report
An 85-year-old female with a history of recurrent urinary
tract infection (UTI) on a background of stage 5 chronic
kidney disease presented with low-grade fever to the
emergency department at Changi General Hospital (CGH)
on 18 July 2013. She had just been discharged from a sub-
acute step down unit at CGH 2 days prior.
Before her index admission to CGH on 9 May 2013, the
patient lived at home with her family, was independent in
her activities of daily living, continent and independently
ambulant with a walking stick. She was on atenolol 100 mg
OM (every morning) and nifedipine LA 60 mg OM for
hypertension, simvastatin 5 mg ON (every night) for
hyperlipidaemia, allopurinol 100 mg OM for gout,
prochlorperazine maleate 5 mg TDS (three times a day) for
dizziness, aqueous cream for dry skin, hypromellose eye
drops, vitamin B complex tablet and calcium and vitamin
D tablet from the outpatient polyclinic. Her baseline esti-
mated creatinine clearance (CrCl) by Cockcroft-Gault was
12–14 mL/min. She was transferred to a community hos-
pital for further rehabilitation on 30 May 2013 but was
readmitted to CGH on 3 July 2013 for new onset seizures
after receiving 8 days of intravenous (IV) ertapenem for a
UTI. She did not have a prior history of seizures. In our
retrospective audit of the notes, she was noted to have
acute-on-chronic kidney injury during her first seizures at
the community hospital, with an estimated CrCl of 10 mL/
min. Despite the small absolute change from 12–14 to 10,
this is a difference of CrCl of 14.3–28.6 % in relative
terms.
IV piperacillin/tazobactam was started empirically on 18
July 2013 on the patient’s third admission to CGH for
presumed recurrent UTI and possible hospital-acquired
infection. She was haemodynamically stable and only had
an intermittent low-grade fever\38 C in the first 2 days
of her admission. She was afebrile from Day 3 onwards and
her white cell count had returned back to normal values by
Day 4.
However, the antibacterial therapy was subsequently
switched to IV ertapenem 500 mg every 24 h (q24h) on
Day 3 in view of positive urine and blood cultures which
grew ESBL-producing Escherichia coli (E. coli). She was
also found at the point of admission to have acute-on-
chronic kidney injury secondary to dehydration, for which
she was started on IV hydration.
Subsequent sensitivity testing revealed that the ESBL-






Upon receiving three doses of ertapenem, the patient
experienced an episode of self-aborted seizure with stiffness
and jerking of all four limbs for a few seconds, followed by
post-ictal drowsiness (Glasgow Coma Scale [GCS] score of
5) on Day 6 of her admission. About 5 h later, she experi-
enced another episode of generalized tonic-clonic (GTC)
seizure that lasted for 2–3 min and self-aborted.
Phenytoin level was checked and its corrected level was
found to be sub-therapeutic at 5.1 mg/L. The primary team
obtained a neurology consult and a loading dose of IV
phenytoin 1000 mg was administered, followed by an
increase of the maintenance dose of oral phenytoin from
200 mg ON to 300 mg ON. A renal consult was also
obtained, and the seizures were not thought to be related to
the degree of azotemia at that point in time (serum urea
20.2 mmol/L, serum sodium 134 mmol/L, serum potas-
sium 4.2 mmol/L, serum creatinine 408 lmol/L). Serum
albumin was 25 g/L. A corrected phenytoin level of
23.7 mg/L was attained 1 day later (slightly above the
upper limit of 20.0 mg/L) and the patient had also regained
a GCS score of 15 by then.
On the 13th day of treatment with ertapenem, the patient
experienced another episode of seizure (1 min duration),
presenting with upward rolling of eyes and left arm jerking.
A repeat neurology consult was of the opinion that this was
a breakthrough seizure due to sepsis. Although IV ertape-
nem was initially planned to be continued beyond 14 days,
this was changed to IV meropenem after consulting with
the resident pharmacist. This was subsequently changed to
IV amikacin by the weekend on-call team in the evening
due to concerns about the possibility of carbapenem-related
seizures. The patient continued to have five further seizures
on Day 14.
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At this point in time, two sequential repeat sets of blood
cultures (aerobic and anaerobic) and urine cultures were
both reported to be sterile, bar one bottle of blood culture.
IV vancomycin was added while awaiting further identifi-
cation. This eventually revealed itself as coagulase-nega-
tive staphylococcus as a result of skin contamination.
Corrected serum calcium and phosphate were both re-
checked and remained normal from admission.
The patient experienced another five episodes of sei-
zures on the following day, Day 15. During this time, IV
lorazepam 4 mg bolus was given twice in addition to a
loading regimen of IV valproate sodium (1200 mg over 2
days followed by 400 mg IV TDS) after additional neu-
rology input to control the status epilepticus.
Repeat serum phenytoin was found to be sub-therapeutic
again at 7.25 mg/L (after correction for low albumin).
Phenytoin was also converted from nasogastric route to IV
100 mg TDS. The dose of phenytoin had been increased to
300 mg ON via nasogastric route 10 days prior to this.
Impaired absorption of phenytoin via the nasogastric route
was thought to be the most likely cause for the sub-thera-
peutic levels [5, 6]. The patient was not admitted to high
dependency care at the family’s request due to advanced
age, advanced chronic kidney disease and expected poor
outcome. GCS at this point was 6/15.
All antibacterials were stopped on Day 16 after review
by the infectious disease consultant. The infectious disease
team was of the opinion that ertapenem was the most likely
underlying trigger for the seizures in view of the negative
cultures and clinical improvement. The patient’s blood
pressure had not been compromised and her temperature
had remained below 38 C since admission 2 weeks pre-
viously. She had not had any episodes of hypoxia, tach-
yarrhythmia or hypoglycaemia under close observation in
the acute admissions ward. There were no other concurrent
medications which could potentially lower the seizure
threshold.
Serum phenytoin remained sub-therapeutic at Day 16 at
8.46 mg/L (after correction), despite the conversion to IV
route, and serum valproic acid levels were also sub-thera-
peutic at 7.05 mg/L. Serum valproic acid levels remained
low at Day 22 at 12.52 mg/L and serum phenytoin
uncorrected was also low at 4.2 mg/L. These low levels are
likely due to the known drug–drug interactions between
intravenous valproic acid and phenytoin. In spite of these
sub-therapeutic levels, the patient remained seizure free
from Day 16, 3 days after the ertapenem was stopped, and
her GCS had improved dramatically to 13/15 by Day 17.
The IV anti-convulsant therapy was converted to naso-
gastric route after 10 days and the doses were subsequently
weaned down and changed to oral levetiracetam
monotherapy 250 mg ON (dose adjusted for advanced
renal failure and age) with no breakthrough seizures.
The patient was discharged 1 month later with slow
stream rehabilitation and has returned home and remained
seizure free to date on the same dose of levetiracetam.
Of note, although the dose of IV ertapenem was kept
constant at 500 mg q24h, we observed the patient had
fluctuating renal function during her treatment with the
antibacterial and the dips in CrCl were in keeping with the
seizure intervals (Fig. 1). In addition, we noted that the
seizures were preceded by episodes of delirium as defined
by the Confusion Assessment Method (CAM) [7].
Discussion
Carbapenems are thought to induce seizures due to the
similarity of the b-lactam ring to the structure of the
inhibitory neurotransmitter c-aminobutyric acid (GABA)
and their antagonism of GABA receptors in the central
nervous system [3]. However, seizures due to ertapenem
are rare and are limited to few case reports to date [3, 8–
11].
Ertapenem is predominantly cleared by the kidneys
(*80 %) with half unchanged and half as a b-lactam open-
ring metabolite, and the remaining 20 % is excreted via the
faeces [12, 13]. The half-life of ertapenem is about 4.5 h in
healthy individuals but it can be increased to 6.1–14.1 h in
the presence of chronic renal impairment [12, 14]. Some
degree of renal dysfunction has been reported in a number
of cases of neurotoxicity associated with ertapenem use [3,
11, 14–16]. It has been proposed that in the presence of
uraemia, the blood–brain barrier is also more permeable
and the protein binding of antibacterials is decreased [4,
11]. In addition, with the accumulation of endogenous
uraemic toxins, a patient may then be more vulnerable to
antibiotic-related neurotoxicity [4].
This is further compounded in elderly ([65 years old)
and very elderly ([80 years old) patients who are known
from population studies to have a high prevalence (about
25 % for silent lacunes, and up to 95 % for white matter
changes/leucoaraiosis) of silent small vessel cerebrovas-
cular disease [17]. This would directly increase the per-
meability of the blood–brain barrier to ertapenem and other
carbapenems.
Miller and colleagues also suggested the presence of
hypoalbuminaemia to be an independent risk factor for
developing seizures with ertapenem compared with other
carbapenems [3].
In the case that we have reported, the patient was a very
elderly woman with underlying chronic kidney disease and
low albumin levels (20–30 g/L). As illustrated in Fig. 1,
her renal function was further compromised due to acute
kidney injury throughout her second treatment with erta-
penem. We noted a trend with the occurrence of her
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seizures corresponding with each drop in her CrCl level,
despite being on a renal-adjusted dose of ertapenem. The
onset of status epilepticus on Day 15 not only coincided
with a drop in her estimated glomerular filtration rate
(eGFR), but also with a drop in her serum phenytoin levels
likely secondary to administration by the nasogastric tube.
The nasogastric tube was inserted after the onset of delir-
ium and first seizures on Day 6 to assist with nutrition and
oral medications.
In a previous case report of a patient with stage 5 chronic
kidney disease who developed neurotoxicity to ertapenem,
the serum ertapenem level was detected to be much higher
than the therapeutic minimum inhibitory concentration
[16]. As such, we believe that the onset of delirium and
seizure activity in relation to dips in our patient’s CrCl
could be a sign of spikes in serum ertapenem level.
In a study by Mistry and colleagues, the estimated
clearance of ertapenem via the non-renal routes was lower in
patients with kidney dysfunction, as compared to the esti-
mated clearance of ertapenem via the non-renal route in
healthy young adults with normal kidney function. This was
based on the extrapolation of the roughly linear relationship
between clearance of ertapenem and creatinine clerance to a
creatinine clearance value of zero (i.e., the y-axis intercept of
the graph, where the y-axis represents plasma clearance of
total ertapenem and the x-axis represents creatinine clear-
ance). They proposed that this finding reinforces that part of
non-renal clearance of ertapenem is facilitated by the kid-
neys and, in the presence of renal dysfunction, renal as well
as non-renal clearance is affected adversely [12].
In addition, the presence of silent chronic microvascular
ischaemic changes and small vessel disease on head CT
performed in both admissions would further predispose our
patient to neurotoxicity with ertapenem. Damage to the
blood–brain barrier as a result of the ischaemic changes
would likely lead to a higher concentration of ertapenem in
brain tissue, the major determinant of CNS toxicity [2].
The number of days-to-onset of our patient’s first sei-
zure (8 days) with the first course of ertapenem was con-
sistent with that reported in various case reports [3, 4, 9,
11]. With re-exposure to ertapenem, her seizures recurred
despite being on an anti-epileptic drug. The last episode of
seizure occurred 2 days after discontinuation of ertapenem
and this could well be explained by taking into consider-
ation the prolongation of ertapenem’s half-life to 6.1–14.1
h in renal impairment and that about five half-lives are
necessary for a drug to be completely cleared.
The patient remained seizure free thereafter despite
repeated sub-therapeutic serum levels of phenytoin and
valproic acid and conversion to single agent oral
monotherapy over the following 4 weeks. Also, we noted a
small rise in serum phosphate on 6 August 2013, 2 days after
the episode of status epilepticus. As the patient remained
well with no further seizures, this is likely to be secondary to
the muscle damage as a result of the seizures and advanced
chronic kidney disease, rather than the cause of the seizures.
In view of the above, the Naranjo Algorithm—a vali-
dated adverse drug reaction probability scale—scored 6 for
our case study, suggesting that the seizure episodes were a
probable adverse drug reaction caused by ertapenem [18].
Naranjo Algorithm Score
Our patient scored 6 based on the following answers to the
questions in the algorithm. We have kept strictly to the
points asked, and only answered yes or no when objective
evidence were available to us:
Fig. 1 Changes in creatinine clearance (Cockcroft-Gault equation) and occurrence of seizures
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1. Yes. There have been previous conclusive reports.
2. Yes. The adverse event appeared after the suspected
drug was administered.
3. Yes. The adverse reaction did improve when the drug
was discontinued (even when the anti-epileptic drug
serum levels were sub-therapeutic).
4. Yes. The reaction did re-appear when the drug was
re-administered 2 days after the first discharge.
5. Yes. There are factors which could have caused the
seizures on their own.
6. We don’t know as no placebo was given to test this.
7. We don’t know as no serum level of ertapenem was
measured.
8. We don’t know as there were no serial serum
ertapenem levels available to answer this objectively.
9. Yes. The patient had the same reaction to the same
drug in a previous admission.
10. We gave this a score of 0 as no EEG was done during
or in between the seizure episodes.
Conclusion
There is a recognizable clinical pattern in the manifestation
of ertapenem-induced delirium and seizures in an ill elderly
patient with multiple morbidities. This is further signposted
by dips in the CrCl if trended over time despite constant
renal-adjusted administration of ertapenem.
We propose that this translates into spikes in serum
levels of ertapenem as a result of further reduction in renal
and extra renal clearance from complex drug–drug, drug–
disease and drug–patient interactions. Discontinuation of
ertapenem therapy should be considered if seizures develop
[19], particularly if the organism is sensitive to other
classes of antibacterials.
Although the incidence of ertapenem and other car-
bapenem-induced seizures are reported to be low in the
general population, more work and studies are required to
quantify the risks for specific sub-groups. A high index of
suspicion is required to detect and report these unseen
adverse drug reactions in the elderly and very elderly
patients.
The findings of our retrospective case note audit for this
case report have been submitted to the patient’s Critical
Medical Information Store (CMIS), part of Singapore’s
Pharmacovigilance Unit reporting system to avoid future
exposure to ertapenem [20].
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